Skip to main content
Clinical Trials/2025-520748-13-01
2025-520748-13-01
Not yet recruiting
Phase 4

Treatment of Chronic Anal Fissure with Ultrasound-Guided Inter-Sphincteric Injections of Botulinum Toxin A

Hospital Universitario de Burgos1 site in 1 country50 target enrollmentJanuary 22, 2025

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Not specified
Sponsor
Hospital Universitario de Burgos
Enrollment
50
Locations
1
Primary Endpoint
VAS scale to quantify pain. Wesner scale to assess fecal incontinence It is a 20-point scale FIQL (Fecal Incontinence Quallity of Life) scale of quality of life, in cases of incontinence. Measurement of the thickness of the EAI by endorectal ultrasound
Status
Not yet recruiting
Last Updated
last year

Overview

Brief Summary

To assess whether the technique of ultrasound-guided botulinum toxin infiltration is more effective and safer than the standard technique, by controlling the infiltration sites. The aim is to analyze whether the location of the botulinum toxin infiltration is an important factor in the result of the treatment. percentage to assess whether the botulinum toxin infiltration is more effective and safer than the standard one. On the other hand, the aim is to standardize a technique and make it much more precise for the localization of the infiltration, through the use of the endorectal ultrasound probe. Therefore, our objective is to establish a novel technique that complements the standard technique, is reproducible and does not increase the risks and is even safer, as it controls the site of toxin infiltration.

Registry
euclinicaltrials.eu
Start Date
January 22, 2025
End Date
TBD
Last Updated
last year
Study Type
Interventional clinical trial of medicinal product

Investigators

Sponsor
Hospital Universitario de Burgos
Responsible Party
Principal Investigator
Principal Investigator

Jorge Labrador

Scientific

Hospital Universitario de Burgos

Eligibility Criteria

Inclusion Criteria

  • All patients of legal age who sign the informed consent form and are diagnosed with chronic anal fissure will be included in the study. Chronic anal fissure will be considered to be that which has been evolving for more than 6 weeks, despite various hygienic-dietary and/or relaxing treatments (NTG) or calcium blockers and which macroscopically presents any of the aspects of chronicity referred to: indurated edges, observation in the fundus of IAF fibers and/or sentinel polyp that persists for more than 6 weeks.

Exclusion Criteria

  • Patients in whom botulinum toxin injection is contraindicated are excluded from the study: patients with alterations of neuromuscular transmission such as myasthenia gravis, Lambert Eaton myasthenic syndrome, inflammatory bowel disease, concomitant treatment with aminoglycosides, pregnancy or lactation, asthma or adverse reactions to treatment.

Outcomes

Primary Outcomes

VAS scale to quantify pain. Wesner scale to assess fecal incontinence It is a 20-point scale FIQL (Fecal Incontinence Quallity of Life) scale of quality of life, in cases of incontinence. Measurement of the thickness of the EAI by endorectal ultrasound

VAS scale to quantify pain. Wesner scale to assess fecal incontinence It is a 20-point scale FIQL (Fecal Incontinence Quallity of Life) scale of quality of life, in cases of incontinence. Measurement of the thickness of the EAI by endorectal ultrasound

Study Sites (1)

Loading locations...

Similar Trials